ACCC Principles for Drug, Diagnostics, and Biomarker Reimbursement

The Association of Community Cancer Centers released a press release requesting Congress, the Health Resources & Services Administration (HRSA), and the Centers for Medicare & Medicaid Services (CMS) that as they work to consider reforms to drug pricing and consider changes to the reimbursement of diagnostics and biomarker testing, that no proposed, modeled, or implemented reimbursement plan negatively impact patient access to care and/or the ability of oncology programs and practices to provide quality cancer care to any patient in need, particularly patients from disadvantaged populations in which health disparities can create poor health outcomes.